| A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) (NCT02821754) | National Cancer Institute (NCI) | 2016-07-05 |
| Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) (NCT06357988) | National Cancer Institute (NCI) | 2016-06-20 |
| Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission (NCT02365480) | National Cancer Institute (NCI) | 2016-06-16 |
| Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma (NCT02709226) | National Cancer Institute (NCI) | 2016-06-15 |
| Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (NCT02636582) | National Cancer Institute (NCI) | 2016-06-14 |
| Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion (NCT02581137) | National Cancer Institute (NCI) | 2016-06-10 |
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (NCT02772003) | National Cancer Institute (NCI) | 2016-06-06 |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (NCT02567435) | National Cancer Institute (NCI) | 2016-06-01 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) (NCT04439123) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (NCT04439201) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) (NCT04439240) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) (NCT04439214) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (NCT04439344) | National Cancer Institute (NCI) | 2016-05-31 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265) | National Cancer Institute (NCI) | 2016-05-23 |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery (NCT02595918) | National Cancer Institute (NCI) | 2016-05-19 |
| Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants (NCT02568566) | National Cancer Institute (NCI) | 2016-05-19 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663) | National Cancer Institute (NCI) | 2016-05-11 |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (NCT02466971) | National Cancer Institute (NCI) | 2016-05-10 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962) | National Cancer Institute (NCI) | 2016-05-09 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (NCT04439149) | National Cancer Institute (NCI) | 2016-05-05 |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (NCT02398773) | National Cancer Institute (NCI) | 2016-05-04 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (NCT02502266) | National Cancer Institute (NCI) | 2016-05-03 |
| Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (NCT02669251) | National Cancer Institute (NCI) | 2016-04-28 |
| FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia (NCT02392429) | National Cancer Institute (NCI) | 2016-04-20 |
| Early Life Exposures in Agriculture (NCT02743481) | National Cancer Institute (NCI) | 2016-04-14 |
| Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib (NCT02759835) | National Cancer Institute (NCI) | 2016-04-13 |
| Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT02535338) | National Cancer Institute (NCI) | 2016-04-11 |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols (NCT02682667) | National Cancer Institute (NCI) | 2016-04-11 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL (NCT02572453) | National Cancer Institute (NCI) | 2016-04-04 |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02446600) | National Cancer Institute (NCI) | 2016-03-28 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (NCT04439188) | National Cancer Institute (NCI) | 2016-03-21 |
| Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test (NCT02734303) | National Cancer Institute (NCI) | 2016-03-17 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (NCT02535312) | National Cancer Institute (NCI) | 2016-03-08 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer (NCT02627430) | National Cancer Institute (NCI) | 2016-03-01 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (NCT04439357) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (NCT04439318) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) (NCT04439305) | National Cancer Institute (NCI) | 2016-02-25 |
| Biomarker Analysis of Central Nervous System Tumors (NCT02692898) | National Cancer Institute (NCI) | 2016-02-25 |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) (NCT04439175) | National Cancer Institute (NCI) | 2016-02-25 |
| Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (NCT02487979) | National Cancer Institute (NCI) | 2016-02-16 |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT02453620) | National Cancer Institute (NCI) | 2016-02-12 |
| Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (NCT02484443) | National Cancer Institute (NCI) | 2016-02-04 |
| Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (NCT02381561) | National Cancer Institute (NCI) | 2016-02-01 |
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies (NCT02659943) | National Cancer Institute (NCI) | 2016-01-21 |
| Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer (NCT02649855) | National Cancer Institute (NCI) | 2016-01-19 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (NCT02474173) | National Cancer Institute (NCI) | 2016-01-15 |
| Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation (NCT02521285) | National Cancer Institute (NCI) | 2016-01-15 |
| Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers (NCT02348203) | National Cancer Institute (NCI) | 2016-01-13 |
| Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma (NCT02659930) | National Cancer Institute (NCI) | 2016-01-13 |
| Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (NCT06303167) | National Cancer Institute (NCI) | 2016-01-08 |
| MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (NCT02407405) | National Cancer Institute (NCI) | 2016-01-07 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) (NCT04439292) | National Cancer Institute (NCI) | 2016-01-04 |
| Prostvac in Patients With Biochemically Recurrent Prostate Cancer (NCT02649439) | National Cancer Institute (NCI) | 2015-12-22 |
| Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue (NCT02594202) | National Cancer Institute (NCI) | 2015-12-21 |
| Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma (NCT02395692) | National Cancer Institute (NCI) | 2015-12-18 |
| Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab (NCT01931098) | National Cancer Institute (NCI) | 2015-12-10 |
| A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (NCT02621021) | National Cancer Institute (NCI) | 2015-12-04 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma (NCT02601209) | National Cancer Institute (NCI) | 2015-11-30 |
| A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (NCT02339571) | National Cancer Institute (NCI) | 2015-11-23 |
| Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (NCT02579967) | National Cancer Institute (NCI) | 2015-11-19 |
| Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (NCT04439331) | National Cancer Institute (NCI) | 2015-11-19 |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) (NCT02544022) | National Cancer Institute (NCI) | 2015-11-13 |
| Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue (NCT02379429) | National Cancer Institute (NCI) | 2015-11-10 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (NCT02506153) | National Cancer Institute (NCI) | 2015-11-10 |
| Gut Microbiota in People With Hepatocellular Carcinoma (HCC) (NCT02599909) | National Cancer Institute (NCI) | 2015-11-06 |
| Iloprost in Preventing Lung Cancer in Former Smokers (NCT02237183) | National Cancer Institute (NCI) | 2015-11-05 |
| Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (NCT02381535) | National Cancer Institute (NCI) | 2015-10-22 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861) | National Cancer Institute (NCI) | 2015-10-21 |
| Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China (NCT02586532) | National Cancer Institute (NCI) | 2015-10-19 |
| Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study) (NCT02566161) | National Cancer Institute (NCI) | 2015-10-01 |
| Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer (NCT02535325) | National Cancer Institute (NCI) | 2015-09-30 |
| Clinical and Laboratory Analysis of Familial Cancer (NCT02565004) | National Cancer Institute (NCI) | 2015-09-28 |
| Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies (NCT02473757) | National Cancer Institute (NCI) | 2015-09-24 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (NCT02356159) | National Cancer Institute (NCI) | 2015-09-24 |
| Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma (NCT02363283) | National Cancer Institute (NCI) | 2015-09-16 |
| Follow-Up Study of People Treated for Scoliosis (NCT02546479) | National Cancer Institute (NCI) | 2015-09-09 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (NCT02224781) | National Cancer Institute (NCI) | 2015-09-08 |
| Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer (NCT02317874) | National Cancer Institute (NCI) | 2015-09-08 |
| Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease (NCT02337517) | National Cancer Institute (NCI) | 2015-09-08 |
| Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors (NCT02319018) | National Cancer Institute (NCI) | 2015-08-27 |
| Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma (NCT02495103) | National Cancer Institute (NCI) | 2015-08-26 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548) | National Cancer Institute (NCI) | 2015-08-18 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (NCT02500797) | National Cancer Institute (NCI) | 2015-08-13 |
| Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) (NCT04439136) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) (NCT04439110) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) (NCT04439253) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) (NCT04439266) | National Cancer Institute (NCI) | 2015-08-12 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) (NCT04439279) | National Cancer Institute (NCI) | 2015-08-12 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02498600) | National Cancer Institute (NCI) | 2015-08-10 |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers (NCT02487095) | National Cancer Institute (NCI) | 2015-07-30 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208) | National Cancer Institute (NCI) | 2015-07-22 |
| Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer (NCT02339558) | National Cancer Institute (NCI) | 2015-07-21 |
| Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer (NCT02504892) | National Cancer Institute (NCI) | 2015-07-21 |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (NCT02415153) | National Cancer Institute (NCI) | 2015-07-14 |
| Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer (NCT02362451) | National Cancer Institute (NCI) | 2015-07-10 |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain (NCT02471339) | National Cancer Institute (NCI) | 2015-07-07 |
| Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial (NCT02275533) | National Cancer Institute (NCI) | 2015-07-02 |